BioPharma Dive August 6, 2024
The startup, which has a COVID treatment in clinical testing, is backed by Apple Tree Partners and funding from BARDA.
Venture firm Apple Tree Partners has invested $55 million in a new biotechnology company developing antiviral treatments capable of working across families of viruses.
The company, called Red Queen Therapeutics, envisions its technology as a foundation for antiviral drugs against infectious pathogens like COVID-19, influenza and respiratory syncytial virus. Already, it has advanced a COVID antiviral through Phase 1 testing, and has secured U.S. government funding for a pan-influenza drug.
Red Queen’s technology is based on research by Harvard Medical School professor Loren Walensky, who co-founded the company alongside Apple Tree Partners. It has designed so-called stapled lipopeptides to block...
Today's Sponsors
Today's Sponsor